"...Now there are tests for several physical indicators of Alzheimer’s, called biomarkers, that can reveal whether there are the telltale toxic proteins of beta-amyloid and tau in the brain. When combined with other information, these results can provide a relatively definitive diagnosis of early-stage Alzheimer’s disease and enable the person to make lifestyle changes, as well as start new treatments or clinical trials right away to attempt to alter its course."

"...Another company, Sacramento, Calif.-based Neurovision, aims to use machine learning to develop retinal scans and blood tests to identify people at risk of developing Alzheimer’s and other forms of dementia. The company's AI model analyzes eye scans for anomalies, like the buildup of certain proteins or blood vessels with a twisted shape, that are associated with Alzheimer’s, said Steven Verdooner, Neurovision's co-founder.

"Our best chance at stopping this disease in its tracks is by advancing the most promising research across the globe. Development of a blood test for biomarker detection and monitoring could be a major step in this process,” said Howard Fillit, M.D., Founding Executive Director and Chief Science Officer at the ADDF.

…"these findings are encouraging because they suggest it may be possible to determine the onset, spread and morphology of AD — a preclinical diagnosis — using retinal imaging, rather than more difficult and costly brain scans,” said senior author Robert Rissman, PhD, professor of neurosciences at UC San Diego School of Medicine.

"We recently discovered that beta-amyloid complexes in the blood can reflect amyloid load in the brain, and we developed technology that allows us to measure these protein complexes in the blood. Our work has shown that the determination of these complexes can identify people at the earliest stages of Alzheimer’s,” said Blaine Roberts, PhD, Associate Professor of Biochemistry at Emory University School of Medicine and co-Investigator.

The collaboration will enable NeuroVision to further validate its retinal imaging technology and develop its technology for potential early detection and monitoring of amyloid pathology related to Alzheimer’s disease.

Twyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing Alzheimer’s Disease Therapeutics, and has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine.

"It is imperative that innovative companies find solutions to this growing threat [millions of Americans living with Alzheimer’s], and that depends on quality organizations providing the resources to support their work,” said Leonard Potter, chief investment officer and president of Wildcat Capital Management.

"This is the first study demonstrating the potential to image and quantify retinal findings related to beta-amyloid plaques noninvasively in living patients using a retinal scan with high resolution", said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center.

"If successful, this technique could one day be used in the clinic to identify at‐risk patients,” said Dr. Michael Rafii, associate professor of neurology at USC and associate professor of neurosciences at UC San Diego.

"NeuroVision is putting together an impressive scientific track record and garnering the attention of other organizations dedicated to finding answers to the threat of Alzheimer’s disease, which often is likened to a developing tsunami,” Leonard Potter said.